Positive Phase III ENCORE for Genzyme's eliglustat in Gaucher's
This article was originally published in Scrip
Executive Summary
Prospects for Genzyme's oral Gaucher disease therapy eliglustat tartrate strengthened on 15 February when the Sanofi-owned company reported positive topline data from the Phase III ENCORE clinical trial on the same day investigators presented detailed results from the Phase III ENGAGE trial at the Lysosomal Disease Network (LDN) WORLD Symposium in Orlando, Florida.